Editas Medicine
EDIT

Editas Medicine (EDIT) analyst forecast and price target

Recent analyst ratings

FirmActionRatingPrice targetDate
Ladenburg ThalmannInitiated CoverageBuy$6.00Aug 18, 2026
Chardan CapitalMaintainedBuy$4.00 from $3.50May 5, 2026
Jones TradingUpgradedHold → Buy$8.00Mar 10, 2026
Chardan CapitalMaintainedBuy$3.50Mar 9, 2026
HC Wainwright & Co.MaintainedBuy$5.00Sep 5, 2025
Wells FargoMaintainedEqual-Weight$4.00 from $3.00Sep 3, 2025
HC Wainwright & Co.MaintainedBuy$5.00 from $3.00Aug 15, 2025
BairdMaintainedOutperform$6.00 from $4.00Aug 13, 2025
BairdMaintainedOutperform$4.00 from $8.00May 13, 2025
HC Wainwright & Co.Initiated CoverageBuy$3.00Apr 28, 2025
JP MorganDowngradedNeutral → UnderweightDec 16, 2024
Evercore ISI GroupMaintainedOutperform$5.00 from $7.00Dec 16, 2024
StifelDowngradedBuy → Hold$3.00 from $11.00Dec 13, 2024
BairdMaintainedOutperform$8.00 from $10.00Dec 13, 2024
Chardan CapitalDowngradedBuy → NeutralDec 13, 2024
BarclaysMaintainedEqual-Weight$3.00 from $5.00Dec 13, 2024
RBC CapitalMaintainedSector Perform$4.00 from $5.00Dec 13, 2024
Wells FargoDowngradedOverweight → Equal-Weight$4.00 from $7.00Dec 11, 2024
BarclaysMaintainedEqual-Weight$5.00 from $7.00Nov 5, 2024
Truist SecuritiesMaintainedBuy$8.00 from $12.00Nov 5, 2024

Frequently asked questions

  • What is the latest analyst rating on EDIT?

    On Aug 18, 2026, Ladenburg Thalmann initiated coverage of Editas Medicine at Buy with a price target of $6.00.

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.